Monte Rosa Therapeutics, Inc. (GLUE) delivered a return of 238.61% over the past year. Since GLUE does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Monte Rosa Therapeutics, Inc. one year ago would be worth $33,861 today, representing a gain of $23,861.

Monte Rosa Therapeutics, Inc. (GLUE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For GLUE, the total return equals the price-only return.

Yes, Monte Rosa Therapeutics, Inc. (GLUE) outperformed the S&P 500 by 215.93 percentage points over the past year. GLUE delivered a total return of 238.61%, compared to the S&P 500's 22.68%. This 215.93pp alpha means investors in GLUE earned more than a passive S&P 500 index fund.

Monte Rosa Therapeutics, Inc. (GLUE) experienced a maximum drawdown of -41.84% over the past year, declining from its peak on 2026-01-08 to its trough on 2026-03-24. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Monte Rosa Therapeutics, Inc. (GLUE)'s long-term returns with dividends reinvested. Over 10 years, the total return is -19.3% (-2.1% CAGR) — $10,000 would have grown to $8,074. Over 20 years: -19.3% total return (-1.1% CAGR) — $10,000 → $8,074. Over 30 years: -19.3% total return (-0.7% CAGR) — $10,000 → $8,074. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Monte Rosa Therapeutics, Inc.'s best calendar year was 2025 with a total return of 120.5%. Its worst year was 2022 with a total return of -62.7%. This range shows the volatility investors should expect — the difference between the best and worst year is 183.2 percentage points.